[1]王莹娟,司同国,杨雪玲,等.冷冻消融联合内分泌治疗T3期转移性前列腺癌的临床疗效及预后分析 [J].介入放射学杂志,2018,27(04):327-333.
　WANG Yingjuan,SI Tongguo,YANG Xueling,et al.Cryoablation combined with endocrine therapy for T3 stage metastatic prostate cancer: clinical efficacy and prognostic analysis[J].journal interventional radiology,2018,27(04):327-333.
点击复制

冷冻消融联合内分泌治疗T3期转移性前列腺癌的临床疗效及预后分析


()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
27
期数:
2018年04期
页码:
327-333
栏目:
肿瘤介入
出版日期:
2018-04-25

文章信息/Info

Title:
Cryoablation combined with endocrine therapy for T3 stage metastatic prostate cancer: clinical efficacy and prognostic analysis
作者:
王莹娟;  司同国;  杨雪玲;  徐 彦;  刘长富;  张炜浩;  郭 志
Author(s):
WANG Yingjuan;  SI Tongguo;  YANG Xueling;  XU Yan;  LIU Changfu;  ZHANG Weihao;  GUO Zhi
Tumor Hospital of Tianjin Medical University， National Clinical Research Center of Cancer， Key Laboratory of Cancer Prevention and Therapy of Tianjin， Tianjin Clinical Research Center for Cancer， Tianjin 300060， China
关键词:
【关键词】 前列腺癌;  冷冻消融;  内分泌治疗
文献标志码:
A
摘要:
【摘要】 目的 探讨冷冻消融（Cryo）联合内分泌治疗在改善T3期转移性前列腺癌预后的意义。方法 回顾性分析103例初治T3期转移性前列腺癌患者临床资料，根据治疗方式不同分为冷冻消融联合内分泌治疗组和内分泌治疗组，内分泌治疗采用全雄激素阻断治疗（maximal androgen blockade，MAB），分析生存预后相关影响因素，比较两组生存预后差异。结果 44例（42.7%）患者接受冷冻消融联合内分泌治疗，59例（57.3%）接受内分泌治疗。预后影响因素分析结果显示：基线PSA≥50 ng/mL、Gleason评分≥8、PSA降至最低值时间（time to psa nadir，TTPN）≤9 个月是总生存（overall survival，OS）预后独立危险因素，联合冷冻消融治疗是OS预后保护因素。合并骨转移、Gleason评分≥8、TTPN≤9个月、PSA最低值>1 ng/mL是无生化复发生存（biochemical recurrence free survival，bRFS）预后独立危险因素，联合冷冻消融治疗是bRFS预后保护因素。联合治疗组和内分泌治疗组平均TTPN分别为11.4个月和7.5个月（P=0.026）、平均PSA最低值分别为（0.99 ng/mL和1.71 ng/mL，P=0.008）、中位OS分别为80个月和 51个月（P<0.001），中位bRFS分别为30个月和12个月（P<0.001）。结论 与内分泌治疗比较，联合冷冻消融治疗可明显延长T3期转移性前列腺癌患者的OS和bRFS，改善患者预后。

参考文献/References:

［1］ Tao ZQ， Shi AM， Wang KX， et al. Epidemiology of prostate cancer： current status［J］. Eur Rev Med Pharmacol Sci， 2015， 19： 805- 812.
［2］ Cornford P， Bellmunt J， Bolla M， et al. EAU- ESTRO- SIOG Guidelines on prostate cancer. Part Ⅱ： treatment of relapsing， metastatic， and castration- resistant prostate cancer［J］. Eur Urol， 2017， 71： 630- 642.
［3］ Kongnyuy M， Halpern DM， Kosinski KE， et al. Cryosurgery， an alternative treatment option for organ- confined prostate cancer： current beliefs and practice patterns of urologists［J］. Int Urol Nephrol， 2017， 49： 43- 48.
［4］ Al Ekish S， Nayeemuddin M， Maddox M， et al. The role of cryosurgery of the prostate for nonsurgical candidates［J］. JSLS， 2013， 17： 423- 428.
［5］ Ward JF， Jones JS. Focal cryotherapy for localized prostate cancer： a report from the national Cryo On- Line Database （COLD） Registry［J］. BJU Int， 2012， 109： 1648- 1654.
［6］ Durand M， Barret E， Galiano M， et al. Focal cryoablation： a treatment option for unilateral low- risk prostate cancer［J］. BJU Int， 2014， 113： 56- 64.
［7］ Nyame YA， Elshafei A， Greene DJ， et al. Prostate specific antigen nadir of 0.1 or less is a predictor of treatment success in men undergoing salvage whole prostate gland cryoablation［J］. J Endourol， 2017， 31： 497- 501.
［8］ Kongnyuy M， Berg CJ， Kosinski KE， et al. Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients［J］. Int J Hyperthermia， 2017， 33： 810- 813.
［9］ 张志田， 郑斐群， 张永胜， 等. MRI评价氩氦刀冷冻治疗前列腺癌16例疗效［J］. 介入放射学杂志， 2015， 24： 527- 529.
［10］ Golabek T， Belsey J， Drewa T， et al. Evidence- based recommendations on androgen deprivation therapy for localized and advanced prostate cancer［J］. Cent European J Urol， 2016， 69： 131- 138.
［11］ Ji GJ， Huang C， Song G， et al. Predictive factor analysis of time to progression of castration- resistant prostate cancer after androgen deprivation therapy［J］. Beijing Da Xue Xue Bao， 2017， 49： 657- 662.
［12］ Mungrue K， Moonan S， Mohammed M， et al. Prostate cancer survival in Trinidad： is PSA a prognostic factor?［J］. Can Urol Assoc J， 2012， 6： E249- E255.
［13］ Dhar N， Ward JF， Cher ML， et al. Primary full- gland prostate cryoablation in older men（＞ age of 75 years）： results from 860 patients tracked with the COLD Registry［J］. BJU Int， 2011，108： 508- 512.
［14］ Yeong J， Sultana R， Teo J， et al. Gleason grade grouping of prostate cancer is of prognostic value in Asian men［J］. J Clin Pathol， 2017， 70： 745- 753.
［15］ Tay KJ， Polascik TJ， Elshafei A， et al. Primary cryotherapy for high- grade clinically localized prostate cancer： oncologic and functional outcomes from the COLD registry［J］. J Endourol，2016， 30： 43- 48.
［16］ James ND， Sydes MR， Clarke NW， et al. Addition of docetaxel，zoledronic acid， or both to first- line long- term hormone therapy in prostate cancer（STAMPEDE）： survival results from an adaptive， multiarm， multistage， platform randomised controlled trial［J］. Lancet， 2016， 387： 1163- 1177.

相似文献/References:

[1]叶 萍,常兆华,韩宝三.乳腺肿瘤冷冻消融治疗的研究进展[J].介入放射学杂志,2011,(08):660.
　YE Ping,CHANG Zhao-hua,HAN bao-san.Research progress in cryoablation therapy for breast tumor[J].journal interventional radiology,2011,(04):660.
[2]孟 冷,张兆琪,王友海,等. 磁共振超高b值弥散序列指导前列腺穿刺的初步研究[J].介入放射学杂志,2012,(07):565.
　MENG Leng,ZHANG Zhao- qi,WANG You-hai,et al. Evaluation of ultra- high-b- value diffusion- weighted MR imaging in diagnosing prostate cancers： a preliminary study[J].journal interventional radiology,2012,(04):565.
[3]韩宗宏,史东宏,许 健,等.氩氦刀联合动脉化疗栓塞治疗16例肾上腺恶性肿瘤[J].介入放射学杂志,2013,(07):553.
　HAN Zong? hong,SHI Dong? hong,XU Jian,et al.Argon?蛳 helium cryoablation combined with transcatheter arterial chemoembolization for the treatment of malignant adrenal neoplasms： initial experience in 16 cases[J].journal interventional radiology,2013,(04):553.
[4]叶伟东,纪建松,涂建飞,等.氩氦刀冷冻消融联合肝动脉栓塞化疗术治疗中晚期肝癌的疗效分析[J].介入放射学杂志,2015,(05):392.
　YE Wei dong,JI Jian song,TU Jian fei,et al.Argon helium cryoablation combined with transcatheter arterial chemoembolization for the treatment of advanced hepatocellular carcinoma： analysis of therapeutic effectiveness[J].journal interventional radiology,2015,(04):392.
[5]张志田,郑斐群,张永胜,等.MRI评价氩氦刀冷冻治疗前列腺癌16例疗效[J].介入放射学杂志,2015,(06):527.
　ZHANG Zhi- tian,ZHENG Fei- qun,ZHANG Yong- sheng,et al.MRI evaluation of argon- helium cryoablation therapy for the treatment of prostate cancer： an analysis of 16 cases[J].journal interventional radiology,2015,(04):527.
[6]邵天朋,刘 丽,袁 磊,等.动脉栓塞联合氩氦刀序贯治疗小肾癌的临床疗效分析[J].介入放射学杂志,2015,(07):597.
　SHAO Tian- peng,LIU Li,YUAN Lei,et al.Sequential therapy of transcatheter arterial embolization combined with percutaneous argon- helium cryoablation for small renal cancers： analysis of clinical effect[J].journal interventional radiology,2015,(04):597.
[7]刘长富,郭 志,邢文阁,等.栓塞联合冷冻消融对比索拉菲尼治疗Ⅲ期肾癌疗效评价[J].介入放射学杂志,2015,(11):964.
　LIU Chang-fu,GUO Zhi,XING Wen-ge,et al.Efficacy comparison for the treatment of stage Ⅲ renal cell carcinoma： transcatheter renal arterial embolization combined with cryoablation vs. sorafenib[J].journal interventional radiology,2015,(04):964.
[8]王 健,李硕玮,陈恕求.前列腺癌125Ⅰ粒子介入治疗手术的护理配合[J].介入放射学杂志,2016,(08):728.
　WANG Jian,LI Shuo-wei,CHEN Shu-qiu.The nursing cooperation in interventional 125I particle treatment for prostate cancer [J].journal interventional radiology,2016,(04):728.
[9]张永远,王 猛,潘元威,等.CT引导氩氦刀冷冻消融治疗滑膜肉瘤的临床疗效初探[J].介入放射学杂志,2018,27(04):345.
　ZHANG Yongyuan,WANG Meng,PAN Yuanwei,et al.CT- guided argon- helium knife cryoablation for the treatment of synovial sarcomas： preliminary results of its clinical efficacy[J].journal interventional radiology,2018,27(04):345.
[10]梅丽丽,曾书娥.超声造影联合实时弹性成像在前列腺穿刺活检中的应用价值探究[J].介入放射学杂志,2019,28(04):347.
　MEI Lili,ZENG Shue..The application value of contrast- enhanced ultrasonography combined with transrectal real- time elastography in prostate biopsy[J].journal interventional radiology,2019,28(04):347.
[11]刘长富,郭 志,司同国,等. 高迁移率族蛋白B1对激素难治性前列腺癌冷冻免疫反应的影响[J].介入放射学杂志,2013,(06):494.
　LIU Chang? fu,GUO Zhi,SI Tong? guo,et al. The effect of high mobility group protein B1 on cryoimmunologic reaction in hormone?蛳 refractory prostate cancer： an experimental study in rats[J].journal interventional radiology,2013,(04):494.

备注/Memo

备注/Memo:
（收稿日期：２０１7-０8-31）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2018-04-16